Biologics Outsourcing Global Market Report 2023 – By Product Type (Antibodies, Recombinant, Vaccines, Protein, Other Products), By Source (Human, Microbial, Other Source), By Application (Oncology, Cellular and Gene Therapy, Blood And Blood-Related Products Development, Vaccine Development, Stem Cell Research, Other Applications), By End User (Pharmaceutical Industries, Biotechnology Industries, Contract Development And Manufacturing Organization(CDMO)) – Market Size, Trends, And Global Forecast 2023-2032

Biologics contract development refers to companies that provide biologics development and manufacturing services to pharmaceutical corporations on a contract basis. The biologics contract development is used to outsource the manufacturing of biologics on contracts to focus on the marketing, R&D, and branding of products. The main source of biologics contract development are microbial, mammalian, and others soruces. The microbial source of biologics contract development are used for the production of various biologics. The biologics contract development indication are oncology, immunological disorders, cardiovascular disorders, hematological disorders, and others indications that are applied in the product service of biologics contract development such as cell line development, process development, and others product services. The global biologics contract development market is segmented - 1) By Source: Microbial, Mammalian, Others Soruces 2) By Indication: Oncology, Immunological disorders, Cardiovascular disorders, Hematological disorders, Others Indications 3) By Product Service: Cell Line Development, Process Development, Others Product Services The global biologics contract development market size is expected to grow from $6.27 billion in 2022 to $7.00 billion in 2023 at a compound annual growth rate (CAGR) of 11.61%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the biologics contract development market is expected to reach $10.29 billion in 2027 at a CAGR of 10.13%. The rising prevalence of chronic diseases is expected to propel the biologics contract development market going forward. Chronic diseases refer to an illness that lasts for a year or longer that requires ongoing medical attention. The rise in chronic disease cases is increasing the demand for developing novel drugs, including biologics, thereby promoting the biologics contract development market. For instance, according to data published in April 2021 by the World Health Organization, a Switzerland-based health organization for international public health, 41 million people die every year due to chronic diseases globally, close to 71% of all deaths. Therefore, the rising prevalence of chronic diseases will drive the growth of the biologics contract development market. Major players in the biologics contract development market are WuXi Biologics, Abzena Ltd., Fujifilm Diosynth Biotechnologies, KBI Biopharma, AGC Biologics, Thermo Fisher Scientific Inc., LakePharma Inc., GenScript, Bionova Scientific Inc., Boehringer Ingelheim BioXcellence, STC Biologics, Siegfried Evionnaz SA, BioAgilytix Labs Inc., Samsung BioLogics, and Forge Biologics. Technological advancements are gaining popularity in the biologics contract development market. Major companies in the biologics contract development market are integrating advanced technologies to sustain their position in the market. For instance, in January 2022, Lonza, a Switzerland-based contract manufacturing and development solutions company, launched bYlok technology platform to design and manufacture bispecific antibodies. It helps to solve the light-heavy chain mispairing issue with high yields, >95% accuracy, and the ability to maintain a mAb-like format. It can be accessed by pharma and biotech companies through a simple research license. In February 2022, Recipharm, a Sweden-based pharmaceutical contract development and manufacturing organization, acquired Vibalogics and Arranta Bio for an undisclosed amount. This acquisition will strengthen Recipharm’s presence in advanced therapy medicinal products and enable it to expand virotherapy manufacturing capabilities in the US. Vibalogics is a Germany-based contract development and manufacturing organization. Arranta Bio is a US-based contract development and manufacturing organization. North America was the largest region in the biologics contract development market share in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics contract development market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biologics contract development market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The biologics contract development market includes revenues earned by entities by sourcing, solid and specialized formulation development, and process analytics development. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The biologics contract development market research report is one of a series of new reports from The Business Research Company that provides biologics contract development market statistics, including biologics contract development industry global market size, regional shares, competitors with a biologics contract development market share, detailed biologics contract development market segments, market trends and opportunities, and any further data you may need to thrive in the biologics contract development industry. This biologics contract development market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biologics testing typically consists of a range of services aimed at evaluating the safety, efficacy, and quality of biological products. The main products of the biologics testing include reagents and kits, instruments and other products. An instrument refers to a tool, device, or machine used to perform experiments, analyze data, or observe biological samples. The various tests included are endotoxin test, sterility test, mycoplasma tests, bioburden tests, residual host-cell proteins and DNA detection tests, virus safety test and other tests types for applications in vaccine development and manufacturing, monoclonal antibodies development and manufacturing, cellular and gene therapy products development and manufacturing, blood and blood products development and manufacturing and other applications. The global biologics testing market is segmented - 1) By Product: Reagents And Kits, Instruments, Other Products 2) By Test Type: Endotoxin Test, Sterility Test, Mycoplasma Tests, Bioburden Tests, Residual Host-Cell Proteins And DNA Detection Tests, Virus Safety Test, Other Test Types 3) By Application: Vaccine Development And Manufacturing, Monoclonal Antibodies Development And Manufacturing, Cellular And Gene Therapy Products Development And Manufacturing, Blood And Blood Products Development And Manufacturing, Other Applications The global biologics testing market size is expected to grow from $4.42 billion in 2022 to $5.09 billion in 2023 at a compound annual growth rate (CAGR) of 15.13%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global biologics testing market size is expected to reach $9.24 billion in 2027 at a CAGR of 16.09%. The rapidly growing pharmaceutical and biotechnology industries are expected to propel the growth of the biologics testing market going forward. The pharmaceutical industry is primarily focused on developing and manufacturing medications for various diseases and medical conditions. The biotechnology industry, on the other hand, focuses on the application of technology to biology and healthcare. Biologics testing includes tests to identify and quantify impurities, assess stability, and evaluate the immune response to the drug. The growth of the pharmaceutical and biotechnology industries has also led to advances in biologics testing technology, such as the development of new analytical tools and techniques. This has allowed for more accurate and efficient testing, reducing the time and cost of bringing new biologics to market. For instance, in June 2022, according to the European Federation of Pharmaceutical Industries and Associations, a Brussels-based trade association and lobbying organization, the European pharmaceutical production increased by 4.64% from € 286,697 million ($307,416 million) in 2020 to € 300,000 million ($321,681 million) in 2021. Further, In 2021, according to Torys LLP, a Canada-based corporate law firm, 84 initial public offerings for biotech companies in the US in 2020 raised a total of US$15 billion. Therefore, the rapidly growing pharmaceutical and biotechnology industries are driving the growth of the biologics testing market. Major players in the biologics testing market are Charles River Laboratories Inc., Thermo Fisher Scientific Inc., Merck KGaA, SGS Société Générale de Surveillance SA, WuXi AppTec Co Ltd., Sartorius AG, Cytovance Biologics Inc., Pace Analytical Services Inc., Avance Biosciences, Eurofins Scientific, Biomerieux SA, Lonza Group Ltd., Genscript Biotech Corp, Bio-Rad Laboratories Inc. and Accugen Laboratories Inc. Product Innovations are a key trend gaining popularity in the biologics testing market. Companies operating in the biologics testing market are adopting new innovative products to sustain their position in the market. For instance, in December 2022, Charles River Laboratories International, Inc., a US-based non-clinical contract research organization, launched the Endosafe® Nexus 200TM, a new addition to its broad endotoxin testing line. The Nexus 200 is a data integrity compliant, fully robotic instrument that is the next step in Charles River's evolution. It uses Endosafe Limulus Amebocyte Lysate (LAL) cartridge technology and can process simple or complex serial dilutions for water, in-process, and final product testing. The system, which is run on Endosafe EndoScan-V version 6.1, enables data to be exported into a Laboratory Information Management System (LIMS) interface and offers enhanced traceability, security, and data management on an integrated touch screen. In December 2021, Thermo Fisher Scientific, a US-based biotechnology company acquired PPD Inc. for $17.4 billion. This acquisition is expected to help Thermo Fisher become a leader in the clinical research services market and to expand its offering. It would bring an effective drug development platform, patient enrollment experience, and strong laboratory capabilities. PPD Inc. is a US-based contract research organization that provides comprehensive, integrated drug development, laboratory, and lifecycle management services. North America was the largest region in the biologics testing market in 2022. Asia-Pacific is expected to be the fastest-growing region in the global biologics testing market duirng the forecast period. The regions covered in the global biologics testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biologics testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The biologics testing market includes revenues earned by entities by providing services such as potency testing, purity testing, sterility testing, immunogenicity testing and others. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The biologics testing market research report is one of a series of new reports from The Business Research Company that provides biologics testing optical components market statistics, including biologics testing optical components industry global market size, regional shares, competitors with a biologics testing optical components market share, detailed biologics testing optical components market segments, market trends and opportunities, and any further data you may need to thrive in the biologics testing optical components industry. This biologics testing optical components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Formulation development outsourcing refers to the practice of hiring external experts or organizations to handle the process of formulating and developing a product. This outsourcing arrangement allows companies to leverage the specialized knowledge, resources, and expertise of external parties to develop or improve the formulation of their products. The main services of formulation development outsourcing are pre-formulation, and formulation development. Preformulation refers to the stage of development in pharmaceutical formulations. The various therapeutic area includes oncology, infectious disease, neurology, hematology, respiratory, cardiovascular, dermatology, others, for various formulations include oral, injectable, topical, other formulations. It is used by various end-user including pharmaceutical industries, research, and academic development. The global formulation development outsourcing market is segmented - 1) By Service: Preformulation, Formulation Development 2) By Therapeutic Area: Oncology, Infectious Disease, Neurology, Hematology, Respiratory, Cardiovascular, Dermatology, Other Therapeutics 3) By Formulation: Oral, Injectable, Topical, Other Formulations 4) By End-User: Pharmaceutical Industries, Research And Academic Development The global formulation development outsourcing market size is expected to grow from $25 billion in 2022 to $27.49 billion in 2023 at a compound annual growth rate (CAGR) of 9.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global formulation development outsourcing market size is expected to reach $39.3 billion in 2027 at a CAGR of 9.3%. Growing chronic diseases are expected to propel the growth of the formulation development outsourcing market going forward. Chronic diseases are conditions that last for a year or longer, require continued medical care, and restrict daily activities. Developing effective formulations and therapies to manage and treat these conditions requires specialized expertise and resources. Formulation development outsourcing engages outside experts or specialized businesses to manage the research, development, and optimization of drug formulations to treat chronic diseases. For instance, in September 2022, according to the World Health Organization, a Switzerland-based intergovernmental organization, chronic diseases affect the lives of 41 million people every year, accounting for 74% of all deaths globally. Additionally, according to the Australian Institute of Health and Welfare, in 2020–21, 11.6 million Australians, or 47% of the population, had one or more chronic illnesses. Therefore, the growing number of chronic diseases is driving the growth of the formulation development outsourcing market. Major players in the formulation development outsourcing market are Syngene International Ltd., Aizant Drug Research Solutions Private Limited., Catalent Inc., Intertek Group plc, Recipharm AB, SGS S.A., Lonza Group AG, Eurofins Scientific SE, Laboratory Corporation of America Holdings, Charles River Laboratories International Inc., Emergent Biosolutions Inc., IRISYS LLC, Piramal Pharma Limited., Biocon Limited., and Dr Reddy's Laboratories Ltd. Technological advancements are a key trend gaining popularity in the formulation development outsourcing market. Companies operating in the formulation development outsourcing market are adopting new technologies, such as artificial intelligence (AI) and machine learning (ML), to sustain their position in the market. For instance, in March 2023, Nvidia, a US-based software technology company, launched BioNeMo Cloud, a new component to their AI Foundations suite. This service offers researchers access to pre-trained AI models, allowing for private data customization. It is aimed to speed up life sciences research, drug discovery, and protein engineering. Amgen, a global biotech giant, and many startups currently use the technology, which is made available as a cloud service and allows for quicker drug development processes. In August 2022, Catalent Inc., a US-based pharmaceutical company, acquired Metrics Inc. for $475 million. This acquisition broadened, diversified and enriched Catalent's portfolio by adding capabilities in integrated oral solid formulation development, manufacturing, and packaging to assist customers in simplifying and accelerating their programs and increasing their capacity to handle highly potent compounds. Metrics Inc. is a US-based global pharmaceutical formulation development organization specializing in novel oral dosage forms. North America was the largest region in the global formulation development outsourcing market in 2022. The regions covered in formulation development outsourcing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the formulation development outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The formulation development outsourcing market includes revenues earned by entities by providing services such as ingredient sourcing, stability studies, analytical testing, and regulatory support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The formulation development outsourcing research report is one of a series of new reports from The Business Research Company that provides formulation development outsourcing statistics, including formulation development outsourcing industry global market size, regional shares, competitors with a formulation development outsourcing share, detailed formulation development outsourcing segments, market trends, and opportunities, and any further data you may need to thrive in the formulation development outsourcing industry. This formulation development outsourcing research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

IT outsourcing refers to the utilization of third-party service providers to supply IT-enabled business processes, application services, and infrastructure solutions for business results. It allows clients to build the finest sourcing strategy and vision, choose the most suitable IT service providers, structure the best contracts possible, and govern arrangements for long-term win-win collaborations with external suppliers. The services involved in IT outsourcing are a software as a service (SaaS), platform as a service (PaaS), and infrastructure as a service (IaaS). SaaS is a software distribution in which a cloud provider hosts programs and makes them available to end customers through the internet. The various organizations involved are small and medium enterprises and large enterprises, which are deployed on public cloud and private cloud. It is used by banking, financial services and insurance (BFSI), healthcare, media and telecommunication, retail and e-commerce, manufacturing, and others. The global IT outsourcing market is segmented - 1) By Service: Software as a Service (SaaS), Platform as a Service (PaaS), Infrastructure as a Service (IaaS) 2) By Organization Size: Small And Medium Enterprises, Large Enterprises 3) By Deployment: Public Cloud, Private Cloud 4) By End-User: Banking, Financial Services And Insurance (BFSI), Healthcare, Media And Telecommunication, Retail And E-Commerce, Manufacturing, Other End-Users The global IT outsourcing market size is expected to grow from $117.61 billion in 2022 to $124.52 billion in 2023 at a compound annual growth rate (CAGR) of 5.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global IT outsourcing market size is expected to reach $150.06 billion in 2027 at a CAGR of 6.3%. The growing adoption of cloud services is expected to propel the growth of the IT outsourcing market going forward. Cloud services combines computation, storage, and network infrastructure to enable rapid application creation and dynamic scaling. IT Outsourcing has grown increasingly prevalent as it allows access to larger global markets. These IT outsourcing functionalities ensures scalability, easier access to subject matter experts, lower costs and to focus resources on core business development. For instance, in January 2023, according to the 2022 State of DevOps Report published by Google, a US-based technology company, in 2022, 26% of users reported using numerous public clouds, up from 21% in 2021. The utilization of hybrid clouds increased from 25% to 42.5%. Therefore, the growing adoption of cloud computing is driving the growth of the IT consulting market. Major players in the IT outsourcing market are International Business Machines Corporation, Accenture PLC, NTT Corporation, Capgemini SE, Dell Technologies Inc., Fujitsu Limited, BMC Software Inc., Hewlett Packard Enterprise Company, CA Technologies Cisco Systems Inc., DXC Technologies, Infosys Limited, Tata Consultancy Services Ltd., Cognizant Technology Solutions Corporation, Wipro Limited, Red Hat Inc., VMware Inc., and Adaptive Computing Enterprises Inc. Technological advancement are a key trend gaining popularity in the IT outsourcing market. Major companies operating in the IT outsourcing market are focused on developing innovative solutions to strengthen their position in the market. For instance, in November 2021, Oracle Corporation, a US-based computer technology corporation, launched Oracle Cloud Infrastructure (OCI) AI services, a set of services designed to make it easier for developers to incorporate AI into their applications without having data science knowledge. It includes OCI language, OCI speech, OCI vision, OCI anomaly detection, OCI forecasting, and OCI data labeling. The uniqueness of this product is that all of these services are at the core of Oracle AI, a set of artificial intelligence, machine learning, and data science capabilities that includes Oracle Digital Assistant, as well as OCI Data Science and Oracle Database Machine Learning, which are used for developing, maintaining, and delivering models based on machine learning. In June 2020, Noventiq Holdings Plc, a UK-based provider of IT solutions and services acquired Aplana Group for an undisclosed amount. With this acquisition, a total of 200 employees with experience in a range of important industries, including finance, the automobile industry, logistics, and other. Further, they will join Softline's team in three Russian research centers (Moscow, Voronezh, and Ufa). Aplana Group is a US-based provider of software development outsourcing services. North America was the largest region in the IT outsourcing market in 2022. Asia-Pacific is expected to be the fastest-growing region in the global IT outsourcing market report during the forecast period. The regions covered in the global IT outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the IT outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The IT outsourcing market includes revenues earned by entities by providing utility services and cloud-enabled outsourcing services, offshoring, onshoring, and nearshoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The IT outsourcing market research report is one of a series of new reports from The Business Research Company that provides IT outsourcing market statistics, including the IT outsourcing industry global market size, regional shares, competitors with IT outsourcing market share, detailed IT outsourcing market segments, market trends, and opportunities, and any further data you may need to thrive in the IT outsourcing industry. This IT outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The healthcare RCM outsourcing refers to the outsourcing of financial processes used by healthcare facilities. It manages administrative and clinical claims processing, payment, and revenue-generating operations. The primary advantage of outsourcing hospital revenue cycle management is that it engages an outside team to handle administrative functions like invoicing, auditing, and other non-provider-related duties. The main type of healthcare RCM outsourcing are pre-intervention, intervention, and post-intervention. Pre-intervention refers to the front-end services or procedure carried out before to an occurrence, an activity, or another. It includes tasks like admitting patients, performing diagnostic tests, scanning, insurance cover and verification. The service offered are of back-end, middle, and front-end, which are used by clinics, hospitals, ambulatory surgery centres, and others. The global healthcare rcm outsourcing market is segmented - 1) By Type: Pre-intervention, Intervention, Post-intervention 2) By Service: Back-end, Middle, Front-end 3) By End User: Clinics, Hospitals, Ambulatory Surgery Centres, Other End users The global healthcare RCM outsourcing market size is expected to grow from $23.66 billion in 2022 to $27.26 billion in 2023 at a compound annual growth rate (CAGR) of 15.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the healthcare RCM outsourcing market is expected to reach $47.79 billion in 2027 at a CAGR of 15%. The rise in healthcare spending is expected to propel the growth of the healthcare RCM outsourcing market going forward. Health expenditure refers to the final spending on 1healthcare goods and services. The growing healthcare expenditures have been driven by direct expenses on new testing and tracing systems, and indirect pandemic costs, such as additional personal protective equipment for frontline healthcare workers. Furthermore, the increasing price and intensity of healthcare-related services have increased government and other institutions' healthcare spending. Due to such an increase in healthcare spending, there is a rise in demand for healthcare RCM outsourcing, which helps to boost provider revenue while minimizing administrative and managing other clinical related activities. For instance, in July 2022, according to OECD Health Statistics 2022, health spending increased by roughly 6% on average in 2021. Additionally, in May 2022, according to JPMorgan Chase & co. report, overall healthcare spending stayed steady between 2019 and 2020 before growing by 23% in 2021. Therefore, increasing healthcare spending would drive the growth of the healthcare RCM outsourcing market. Major players in the healthcare RCM outsourcing market are Conifer Health Solutions, MedAssets, R1 RCM, McKesson, Parallon Business Solutions , The SSI Group, Cerner Corporation, Cognizant, Optum360, Greenway Health LLC, Medvertex, International Business Machines Corporation, MediRevv, Drchrono Inc., Pulse Systems Inc., edgeMED Healthcare, MediRevv, and Greenway Health LLC. Technological innovation is a key trend gaining popularity in healthcare RCM outsourcing. Major companies operating in the healthcare RCM outsourcing market are focused on delivering innovative solutions by incorporating artificial intelligence and machine learning in their RCM processes. Machine learning is a subfield of artificial intelligence and computer programming that utilizes algorithms and data to mimic the ways of human knowledge and gradually improve its accuracy. For instance, in June 2022, Olive AI, a US-based automation company creating the internet of healthcare, launched an autonomous revenue cycle (ARC) system to automate the revenue cycle management process in healthcare. Olive's ARC reshapes RCM by reducing manual chores through intelligent automation, allowing healthcare businesses to focus more on patient care and reducing employee stress. It combines with pre-existing EHR and practise management systems to use an organization's data sources and claims data over time to become more intelligent and efficient. In June 2022, Linden Capital Partners, a Chicago-based private equity firm focused on the healthcare industry, acquired Aspiron for an undisclosed amount. With this acquisition, the board will co-operate with the Aspirion team to accomplish Linden and management's shared vision of driving a step change improvement in RCM solutions, offering greater benefits for healthcare providers and the patient they serve. Aspiron is a US-based revenue cycle management (RCM) company for hospitals and health care. North America was the largest region in the healthcare RCM outsourcing market share in 2022. The regions covered in the healthcare RCM outsourcing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the healthcare RCM outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The healthcare RCM outsourcing market includes revenues earned by entities by providing administrative functions, address coding/billing issues, revenue management solution. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The healthcare RCM outsourcing market research report is one of a series of new reports from The Business Research Company that provides healthcare RCM outsourcing market statistics, including healthcare RCM outsourcing industry global market size, regional shares, competitors with a healthcare RCM outsourcing market share, detailed healthcare RCM outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the healthcare RCM outsourcing industry. This healthcare RCM outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hospital outsourcing is a process in which some processes of a hospital are assigned to another vendor or a smaller facility that has expertise and specialization in the specific area. This helps to provide support to hospital processes and smooth running of the hospitals. The main types of hospitals in the hospital outsourcing market are private and public. A private hospital refers to a hospital that is not owned by the government, these hospitals provide various types of services and activities conducted for the development and smooth function of hospitals. The various sizes of hospitals include small and medium hospitals and large hospitals that provide several services such as healthcare IT, clinical services, business services, transportation services, and others. The various end-users include nursing homes and assisted living, specialty hospitals, general medical and surgical hospitals, emergency and other outpatient care centers, and others. The global hospital outsourcing market is segmented - 1) By Hospital Type: Private, Public 2) By Hospital Size: Small and Medium Hospitals, Large Hospitals 3) By Services: Healthcare IT, Clinical Services, Business Services, Transportation Services, Other Services 4) By End-Users: Nursing Homes and Assisted Living, Speciality Hospitals, General Medical and Surgical Hospitals, Emergency and Other Outpatient Care Centers, Other End Users The global hospital outsourcing market size grew from $327.9 billion in 2022 to $375.1 billion in 2023 at a compound annual growth rate (CAGR) of 14.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The hospital outsourcing market size is expected to grow to $612.24 billion in 2027 at a CAGR of 13.0%. The increase in diabetic patient flow in hospitals is expected to propel the growth of the hospital outsourcing market going forward. Hospitals opt for outsourcing services when there is an increase in patients and the hospital infrastructure is not capable of handling a large number of patients. This is a result of the rise in chronic illnesses, including diabetes, cardiovascular disease, and others, which are increasing the number of patients being admitted to hospitals and, eventually, placing greater pressure on medical procedures. For instance, according to the International Diabetics Federation (IDF) report, a Belgium-based diabetic organization, in the year 2021, approximately 537 million adults in-between the age group 20-79 years were living with diabetes and it is estimated to rise to 643 million by 2030 and 783 million by 2045. Therefore, the increase in diabetic patient flow in hospitals is driving the growth of the hospital outsourcing market. Major players in the hospital outsourcing market are AllScripts Healthcare Solutions Inc., Cerner Corporation, Sodexo S.A., LogistiCare Solutions LLC, The Allure Group, Aramark Corporation, Alere Inc., Flatworld Solution, Integrated Medical Transport, ABM Industries Inc., Abbott Laboratories, 3M Company (3M Health Information Systems), and TriMedx LLC. Technology advancements have emerged as the key trend gaining popularity in the hospital outsourcing market. Major companies operating in the hospital outsourcing sector are focused on introducing technological innovations to sustain their position in the market. For instance, in May 2020, HSG Advisors, a US-based national healthcare consulting firm, launched an advanced Virtual Health consulting service which can be used in hospitals, and healthcare systems. This virtual health service helps doctors to visit patients virtually for regular checkups. This is based on AI (artificial intelligence) technology, which helps to book appointments easily and allocate time slots with doctors. In March 2021, Omega Healthcare, a US-based company operating in outsourced revenue cycle management and other hospital support services, acquired Himagine Solutions Inc. for an undisclosed amount. Through this acquisition, Omega Healthcare aims to expand its service capabilities and the ability to service clients globally with a more integrated end-to-end solution. Additionally, Omega healthcare also aims to gain Himagine’s expertise in clinical documentation improvement (CDI) for coding audits, and chart abstraction for medical registries including United States cancer and trauma registries. Himagine Solutions Inc. is a US-based company that provides hospital outsourcing services such as medical coding, coding audit, registry management, and others. North America was the largest region in the hospital outsourcing market in 2022. The regions covered in the hospital outsourcing market share report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the hospital outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The hospital outsourcing market includes revenues earned by entities by providing medical administration, medical transcription, it systems management and consultancy services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced.It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The hospital outsourcing market research report is one of a series of new reports from The Business Research Company that provides hospital outsourcing market statistics, including hospital outsourcing industry global market size, regional shares, competitors with a hospital outsourcing market share, detailed hospital outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the hospital outsourcing industry. This hospital outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The automotive transmission engineering services outsourcing refer to services that provide outsourced development assistance for cutting-edge powertrain systems. Automotive transmission engineering is an important process in the manufacturing of automobiles and it is done to make sure that the power flow from the engine to the wheels for ensuring the movement of the vehicle. The main service types of automotive transmission engineering services outsourcing are designing, prototyping, testing, system engineering and integration, and simulation. The designing services include expert knowledge and modelling components, concept generation and assessment, and using components that are automatically proportioned. The designing services also include providing a fresh set of driveline components or systems to utilise as a starting point for the final design. The two types of powertrains are conventional and hybrid which support automatic and manual transmission types. The automotive transmission engineering services outsourcing services are applied for commercial automotive, industrial automotive, and passenger automotive. The global automotive transmission engineering services outsourcing market is segmented - 1) By Service Type: Designing, Prototyping, Testing, System Engineering and Integration, Simulation 2) By Powertrain: Conventional, Hybrid 3) By Transmission Type: Automatic, Manual 4) By Application: Commercial Automotive, Indstrial Automotive, Passenger Automotive The global automotive transmission engineering services outsourcing market size will grow from $11.72 billion in 2022 to $12.24 billion in 2023 at a compound annual growth rate (CAGR) of 4.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global automotive transmission engineering services outsourcing market is expected to grow to $14.54 billion in 2027 at a CAGR of 4.4%. The increasing production of vehicles and rising demand for hybrid vehicles will propel the growth of the automotive transmission engineering services outsourcing market during the forecast period. A hybrid automobile has two or more engines, one of which is an electric motor and the other is a traditional engine either petrol or diesel. The benefit of a hybrid car over a gasoline-powered car is leading an increase in automotive vehicles, resulting in the growth of the automotive transmission engineering services outsourcing across the globe. For instance, In 2021, hybrid vehicles accounted for 19.6% of all new passenger cars sold in The EU region. This is increased from the 11.9 % market share that was held in 2020. The environmentally friendly nature of hybrid vehicles has increased the demand for hybrid vehicles and it is driving the automotive transmission engineering services outsourcing market. The technological advancements in automotive transmission are a key trend followed in the automotive transmission engineering services outsourcing market. Adaptation of new technological advancements by companies is resulting in a major growth opportunity in the automotive transmission engineering services outsourcing market. For instance, in June 2021, IAV and the Massachusetts Institute of Technology (MIT) initiated a cooperative research project for alternative propulsion systems in June 2021, analysing and assessing various drive types in heavy-duty vehicles based on hydrogen, electrification, hybridization, and methane combustion. In February 2021, Apollo Future Mobility Group Limited, a China-based mobility technology solution provider acquired Ieenion Automobile AG for an un-disclosed amount. This acquisition will help the Apollo Future Mobility Group Limited to expand its new energy vehicle solutions as well as services and become a leading full-service provider. Ideenion Automobil AG is a Germany-based automotive engineering services outsourcing (ESO) provider. Major players in the automotive transmission engineering services outsourcing market are AVL GmbH, FEV GmbH, IAV GmbH, Ricardo PLC., Intertek Group PLC., Porsche Engineering, Tata Consultancy Services Limited, Magna International Inc., Magneti Marelli S.p.A, Horiba, Ltd., Intertek Group plc, Dr. Ing. h.c. F. Porsche AG., Marelli Holdings Co., Ltd., Bertrandt AG, ALTEN Group, Altran, AISIN SEIKI Co., Ltd., ZF Friedrichshafen AG, Schaeffler Engineering GmbH, Continental AG, Eaton, and Smart Manufacturing Technology Ltd. Asia-Pacific was the largest region in the automotive transmission engineering services outsourcing market share in 2022. The regions covered in the global automotive transmission engineering services outsourcing market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the automotive transmission engineering services outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The automotive transmission engineering services outsourcing market includes revenues earned by entities by providing services such as backward vertical integration, conglomerate integration, forward vertical integration, horizontal integration. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The automotive transmission engineering services outsourcing market research report is one of a series of new reports from The Business Research Company that provides automotive transmission engineering services outsourcing market statistics, including automotive transmission engineering services outsourcing industry global market size, regional shares, competitors with an automotive transmission engineering services outsourcing market share, detailed automotive transmission engineering services outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the automotive transmission engineering services outsourcing industry. This automotive transmission engineering services outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biologics are medications made from organic materials that can be used to treat a wide range of illnesses, and they are frequently used to treat immune-related illnesses such Crohn's disease, psoriasis, ankylosing spondylitis, and rheumatoid arthritis. The interesting aspect is that biologics are separated from various natural sources, whether they be carbohydrates, proteins, nucleic acids, or a complex mixture of these materials. The main types of biologics are monoclonal antibodies (MAbs), therapeutic proteins, and vaccines. Monoclonal antibodies, or mAbs, are created in a laboratory to combat a specific infection. The various route of administration includes oral, parenteral, and others that are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global biologics market is segmented - 1) By Type: Monoclonal Antibodies (MAbS), Therapeutic Proteins, Vaccines 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Other Distribtuion Channels 3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs Subsegments Covered: Anti-Cancer MAbS, Immunological MAbS, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological MABS, Cardiovascular And Cerebrovascular MAbS, Other Monoclonal Antibodies (MAbs), Metabolic Disorders Therapeutic Proteins, Cancer Therapeutic Proteins, Cardiovascular Therapeutic Proteins, Immunological Therapeutic Proteins, Other Therapeutic Proteins, Anti-Infective Vaccines, Autoimmunity Vaccines, Other Vaccines The global biologics market size is expected to grow from $382.04 billion in 2022 to $416.65 billion in 2023 at a compound annual growth rate (CAGR) of 9.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, and affecting many markets across the globe. The market size of global biologics market is expected to reach $599.62 billion in 2027 at a CAGR of 9.5%. Technology is expected to be a continued driver of market growth during this period. An area of particular development is likely to be physiology simulation modeling. Markets such as this one will benefit from the greater efficiencies offered by developments in this area. For example, Eli Lilly and Pfizer have adopted Amazon’s Elastic Compute Cloud (EC2) platform to conduct simulation models in early drug discovery that have been operational within hours, whereas traditional models would have taken weeks to conduct simulations. The Open Innovation Drug Discovery program is another initiative by Lilly to enhance the research and development of biologics. Such technological advances are likely to reduce costs and expedite the development phase of biologics, allowing companies to launch their products early. Major companies in the biologics market include AbbVie, Johnson & Johnson, Amgen, Sanofi S.A, F. Hoffmann-La Roche Ltd., GlaxosmithKline, Novartis AG, Pfizer Inc., Teva Pharmaceuticals and CSL. The early generation of biologics is losing its patent protection and is expected to face greater competition going forward from the entry of biosimilars into the market. Biosimilars are pharmaceuticals that are developed to have similar properties to a biological drug that has already been approved. Demand for biosimilars is being fueled by governments around the world trying to reduce healthcare costs. In India, a new biosimilar policy called the ‘Guidelines on Similar Biologics’ prepared by the Central Drugs Standard Control Organization (CSDCO) is expected to give a major boost to the Indian biosimilars industry. In the EU, a pathway for approving biosimilar medicines has existed since 2003. These less expensive alternatives increase the competitiveness of the biologics market putting downward pressure on pricing and market value growth. The US Food and Drug Administration (FDA) has revised its regulations to eliminate outdated biologics requirements, thus allowing drug manufacturers to employ new manufacturing technologies and testing capabilities. Standard preparations (standard solutions containing a precisely known concentration of an element), which help to ensure the safety, purity, and potency of biologics can now be obtained from sources other than FDA’s Center for Biologics Evaluation and Research (CBER) or can be developed internally by the biologics license applicant. The FDA has also removed a rule (Section 610.21 of FDA code) that specifies minimal potency limits to be met for certain antibodies and antigens. In addition, FDA is also updating regulations (Section 610.53 of FDA code) regarding storage periods and storage conditions for biologics. These amendments in regulations are expected to increase regulatory flexibility by allowing the pharmaceutical industry and the FDA to incorporate current scientific technologies in the manufacture of licensed biological products. North America was the largest region in the biologics market share in 2022. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the global biologics market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biologics market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The biologics market consists of sales of Tumor necrosis factor inhibitors, Interleukin inhibitors, B-cells inhibitors, and T-cells inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The biologics market research report is one of a series of new reports from The Business Research Company that provides biologics market statistics, including biologics industry global market size, regional shares, competitors with a biologics market share, detailed biologics market segments, market trends, and opportunities, and any further data you may need to thrive in the biologics industry. This biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.